Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc (AMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,149,592
  • Shares Outstanding, K 314,363
  • Annual Sales, $ 2,794 M
  • Annual Income, $ -116,890 K
  • EBIT $ 358 M
  • EBITDA $ 623 M
  • 60-Month Beta 1.34
  • Price/Sales 1.41
  • Price/Cash Flow 9.55
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 110.33% (+8.45%)
  • Historical Volatility 24.41%
  • IV Percentile 84%
  • IV Rank 62.92%
  • IV High 173.90% on 12/08/25
  • IV Low 2.47% on 09/09/25
  • Expected Move (DTE 7) 0.74 (5.71%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 282
  • Volume Avg (30-Day) 142
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 7,500
  • Open Int (30-Day) 8,504
  • Expected Range 12.22 to 13.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.16
  • Number of Estimates 2
  • High Estimate 0.18
  • Low Estimate 0.14
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.86 +9.23%
on 12/10/25
13.48 -3.89%
on 01/08/26
+0.99 (+8.27%)
since 12/09/25
3-Month
9.56 +35.56%
on 10/15/25
13.48 -3.89%
on 01/08/26
+2.67 (+25.95%)
since 10/09/25
52-Week
6.68 +94.01%
on 04/10/25
13.48 -3.89%
on 01/08/26
+4.90 (+60.79%)
since 01/08/25

Most Recent Stories

More News
Can This Healthcare Stock Keep Going After a Nearly 70% Surge?

Amneal Pharmaceuticals (AMRX) is trading at new 5-year highs with strong technical momentum. AMRX has gained 69% over the past year. Shares maintain a 100% “Buy” technical opinion on Barchart. Analyst...

AMRX : 12.96 (-1.82%)
1 Profitable Stock with Exciting Potential and 2 Facing Headwinds

1 Profitable Stock with Exciting Potential and 2 Facing Headwinds

ULH : 17.09 (+2.83%)
EME : 646.27 (+2.87%)
AMRX : 12.96 (-1.82%)
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

Approvals expand Amneal’s biosimilars portfolio Company expects to commercialize six biosimilars across eight presentations by 2027 BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal...

AMRX : 12.96 (-1.82%)
1 Small-Cap Stock to Target This Week and 2 That Underwhelm

1 Small-Cap Stock to Target This Week and 2 That Underwhelm

LMAT : 85.00 (-0.05%)
AMRX : 12.96 (-1.82%)
PIPR : 361.19 (-1.81%)
Amneal Receives U.S. FDA Approval for Epinephrine Injection in Single- and Multi-Dose Vials for U.S. Hospitals

Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals,...

AMRX : 12.96 (-1.82%)
Amneal Announces Positive Interim Phase 4 ELEVATE-PD Results With CREXONT® for Parkinson’s Disease

Interim data show substantial improvements in “Good On” time compared to other oral CD/LD therapies CREXONT delivered substantial “Off” time reductions, improved motor symptom control and provided...

AMRX : 12.96 (-1.82%)
3 Healthcare Stocks We’re Skeptical Of

3 Healthcare Stocks We’re Skeptical Of

JAZZ : 161.13 (+0.55%)
AZTA : 37.92 (+1.12%)
AMRX : 12.96 (-1.82%)
Amneal to Participate in Upcoming Investor Conferences

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, and Tasos Konidaris, Chief Financial...

AMRX : 12.96 (-1.82%)
Amneal Receives U.S. FDA Approval for Albuterol Sulfate Inhalation Aerosol

BRIDGEWATER, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has...

AMRX : 12.96 (-1.82%)
Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

Approval underscores Amneal’s advanced sterile manufacturing capabilities and expansion within complex ophthalmic therapies; Launch expected in Q1 2026  BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE...

AMRX : 12.96 (-1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amneal Pharmaceuticals LLC is an integrated specialty pharmaceutical company. It focused on developing, manufacturing and distributing generic, brand and biosimilar products. The company operates primarily in North America, Asia and Europe. Amneal Pharmaceuticals LLC, formerly known as Impax Laboratories...

See More

Key Turning Points

3rd Resistance Point 13.58
2nd Resistance Point 13.45
1st Resistance Point 13.20
Last Price 12.96
1st Support Level 12.82
2nd Support Level 12.69
3rd Support Level 12.44

See More

52-Week High 13.48
Last Price 12.96
Fibonacci 61.8% 10.89
Fibonacci 50% 10.08
Fibonacci 38.2% 9.28
52-Week Low 6.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar